- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01498627
Cervarix Long-term Safety Surveillance (PGRx)
Cervarix Long-term Safety Surveillance Using the PGRx Information System (PGRx Study)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
PGRx is an information system that intends to bridge the resource gap to assess the effect of a drug on the risk of adverse events that are infrequent and/or with a long delay of onset. It uses some characteristics of the ad hoc case-control or case-referent design, transposed on a prospective, on-going, population-based recruitment plan. This particular design is called here systematic case-referent design in contrast to the ad hoc case-control or case-referent methodology. The PGRx information system is based on the routine and targeted recruitment of cases of a series of pathologies, compared to population-based referents for the study of exposure to a wide variety of drugs. Drug exposure ascertainment is obtained from two different sources in the PGRx.
system: A) A structured patient interview (telephone-administered questionnaire) B) The medical data form with the computerized medical prescriptions (interview guide)
Type d'étude
Inscription (Réel)
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Male and female
- Age 14 to 79 years-old (included)
- Patient residing in France
- Patient accepting to participate in the study
- Patient can read and respond to a telephone interview
Exclusion Criteria:
- Prior reported history of the disease
- Patient or Patient's parent cannot read the interview guide or answer a telephone interview questionnaire in French
- Refusal to participate
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: Cas-témoins
- Perspectives temporelles: Éventuel
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
---|---|
Case Group
Subjects in this group are incident cases (i.e.
newly diagnosed subjects) reported as having occurred in the previous twelve months before the recruitment consultation.
|
3 doses over a period of 6 months (Month 0 and ideally Month 1 and Month 6, with 1 month minimum between any two doses).
PGRx information system
|
Control Group
Subjects selected from the pool of potential referents reported by physicians in general practice, who meet the same general inclusion and exclusion criteria as the cases.
|
3 doses over a period of 6 months (Month 0 and ideally Month 1 and Month 6, with 1 month minimum between any two doses).
PGRx information system
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
To assess whether the use of Cervarix® is associated with a modified risk of central demyelination.
Délai: At Month 36
|
At Month 36
|
To assess whether the use of Cervarix® is associated with a modified risk of type 1 diabetes.
Délai: At Month 36
|
At Month 36
|
To assess whether the use of Cervarix® is associated with a modified risk of cutaneous Lupus.
Délai: At Month 36
|
At Month 36
|
To assess whether the use of Cervarix® is associated with a modified risk of inflammatory arthritis.
Délai: At Month 36
|
At Month 36
|
To assess whether the use of Cervarix® is associated with a modified risk of idiopathic thrombocytopenic purpura.
Délai: At Month 36
|
At Month 36
|
To assess whether the use of Cervarix® is associated with a modified risk of systemic lupus erythematosus.
Délai: At Month 36
|
At Month 36
|
To assess whether the use of Cervarix® is associated with a modified risk of addendum for cutaneous lupus.
Délai: At Month 36
|
At Month 36
|
To assess whether the use of Cervarix® is associated with a modified risk of myositis.
Délai: At Month 36
|
At Month 36
|
To assess whether the use of Cervarix® is associated with a modified risk of dermatomyositis.
Délai: At Month 36
|
At Month 36
|
To assess whether the use of Cervarix® is associated with a modified risk of Guillain-Barrre syndrome.
Délai: At Month 36
|
At Month 36
|
To assess whether the use of Cervarix® is associated with a modified risk of autoimmune thyroiditis
Délai: At Month 36
|
At Month 36
|
To assess whether the use of Cervarix® is associated with a modified risk of Graves disease.
Délai: At Month 36
|
At Month 36
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- 112677
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Infections, Papillomavirus
-
West Virginia UniversityInscription sur invitationInfection de la peau et des tissus mous | Infection gastro-intestinale | Infection pulmonaire | Infection des os et des articulations | Infection endovasculaire | Infection génito-urinaireÉtats-Unis
-
Radboud University Medical CenterSint MaartenskliniekActif, ne recrute pasInfection du site opératoire | Infection articulaire | Infection, site chirurgical | Prothèse Infection Hanche et Genou | Infection liée aux prothèses | InfectionProPays-Bas
-
Croydon Health Services NHS TrustComplétéInfection du site opératoire | Infection de la plaie | Césarienne; Infection | Infection périnéaleRoyaume-Uni
-
Taipei Medical University WanFang HospitalInconnue
-
Ondine Biomedical Inc.ComplétéInfection du site opératoire | Infection nosocomiale | Infection associée aux soins de santéÉtats-Unis
-
Angela BiancoStryker NordicRésiliéCésarienne | Infection du site opératoire | Infection nosocomialeÉtats-Unis
-
Gundersen Lutheran Medical FoundationGundersen Lutheran Health SystemComplétéInfection du site opératoire | Infection superficielle du site opératoire | Infection profonde du site chirurgical | Infection du site chirurgical d'un organe/de l'espaceÉtats-Unis
-
Leiden University Medical CenterRadboud University Medical Center; University Medical Center Groningen; Erasmus... et autres collaborateursRecrutementInfection prothétique-articulaire | Infection de la hanche | Infection; Genou, ArticulationPays-Bas
-
Cairo UniversityRecrutementInfection postopératoire | Complications de la césarienne | Infection vaginaleEgypte
-
Hospices Civils de LyonRecrutement